United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $235.35, for a total value of $847,260.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,595.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $255.14 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The business’s 50 day moving average price is $234.62 and its 200-day moving average price is $228.81. The firm has a market capitalization of $11.32 billion, a PE ratio of 12.86 and a beta of 0.54. United Therapeutics Co. has a 1 year low of $204.44 and a 1 year high of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 earnings per share. As a group, equities research analysts expect that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on UTHR shares. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Wells Fargo & Company boosted their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Wedbush restated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

Institutional Trading of United Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Rise Advisors LLC acquired a new position in United Therapeutics during the first quarter worth $32,000. GAMMA Investing LLC acquired a new position in United Therapeutics during the fourth quarter worth $43,000. Benjamin F. Edwards & Company Inc. boosted its stake in United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. acquired a new position in United Therapeutics during the third quarter worth $91,000. Finally, Janiczek Wealth Management LLC boosted its stake in United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.